Can Fite rises as it submits market registration plan to EMA for psoriasis treatment

Can Fite Biopharma

10/01/2023 13:24

** U.S.-listed shares of Israel-based Can Fite Biofarma Ltd
 CANF.K  rise ~9% premarket to $7.12
    ** Co says it submitted a marketing registration plan to the
European Medicines Agency (EMA) for its lead drug candidate
piclidenoson in the treatment of moderate to severe psoriasis
    ** A submission to the U.S. Food and Drug Administration
will follow - CANF
    ** The submission is based on results from late-stage study
testing the safety and efficacy of the drug
    ** Psoriasis is a skin disease that causes itchy skin with
scaly patches
    ** Co lost ~52% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))